Yale Universities to Join Myasthenia Gravis Clinical Trials Network

Clinical Trials can Offer High Quality Care Options at no Cost in Salt Lake City, Utah

The National institutes of Health (NIH), through the Rare Diseases Clinical Research Consortia (RDCRC), has awarded a research team from Yale University, George Washington University, and Duke University $7.8 million to establish a rare disease network for myasthenia gravis (MGNet).

Myasthenia gravis

Characterized by weakness and rapid fatigue of any of the muscles under voluntary control reports YaleNews’ Bill Hathaway. The symptoms of Myasthenia can range from arm and leg muscle weakness to double vision, drooping eyelids and difficulties with speech, chewing, swallowing and even breathing.

Seven Study Sites

This new Myasthenia network will include a network that involves 7 study sites and ultimately be part of 25 established NIH RDCRCs (NCATS Rare Disease Network). The network will also include basic and clinical investigators, patient advocacy groups, and biotechnology and pharmaceutical companies collaborating to enhance therapeutic research and development in the rare disease segment.

The Principal Investigators

Kevin C. O’Connor, Yale University

Richard J. Nowak, Yale University

Linda Kusner, George Washington University                             

Jeffrey T. Guptill, Duke University